Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: A randomized controlled trial

Transplantation

Volumn 81, Issue 7, 2006, Pages 1035-1040

  Meier, Markus ^a   Nitschke, Martin ^a   Weidtmann, Britta ^a   Jabs, Wolfram J ^a   Wong, Waichi ^b   Suefke, Sven ^a   Steinhoff, Juergen ^a   Fricke, Lutz ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chronic allograft nephropathy; Cyclosporine; Tacrolimus; Transplantation

Indexed keywords

AMLODIPINE; AZATHIOPRINE; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLONIDINE; CORTICOSTEROID; CYCLOSPORIN A; DIHYDRALAZINE; DOXAZOSIN; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LERCANIDIPINE; LOSARTAN; METHYLPREDNISOLONE; METOPROLOL; MINOXIDIL; MOXONIDINE; NIFEDIPINE; PRAZOSIN; RAMIPRIL; SPIRONOLACTONE; TACROLIMUS; TORASEMIDE; UNINDEXED DRUG; URAPIDIL; VALSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CHRONIC DISEASE; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646350026     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000220480.84449.71     Document Type: Article

References (25)

1. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescense. J Am Soc Nephrol 1999; 10: 167-181.
2. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomized multi-center study. Lancet 2002; 359: 741-746.
3. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-756.
4. Gjertson DW. Impact of delayed graft function and acute rejection on graft survival. Tranplant Proc 2002; 3: 982-987.
5. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States 1988 to 1996. N Engl J Med 2000; 342: 605-612.
6. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590.
7. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64: 2047-2073.
8. Artz MA, Boots JMM, Lightenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2004; 14: 1880-1888.
9. Artz MA, Boots JMM, Lightenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937-945.
10. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004; 77: 1199-1202.
11. Fricke L, Doehn C, Steinhoff J, et al. Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy? Transplantation 1998; 65: 1182-1187.
12. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus in combination with azathioprine or mycophenolate mofetil versus cyclosporine with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 9: 834-841.
13. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
14. Stoves J, Newstead CG, Baczkowski AJ, et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2113-2120.
15. Cantarovich D, Renou M, Megnigbeto A, et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation 2005; 79: 72-78.
16. Hohage H, Welling U, Heck M, et al. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors. Int Immunopharmacol 2005; 5: 117-123.
17. Esposito C, Foschi A, Parrilla B, et al. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. Transplant Proc 2004; 36: 693-697.
18. Murphy GJ, Waller JR, Sandford RS, et al. Randomized clinical trial of the effect of microemulsion cyclosporine and tacrolimus on renal allograft fibrosis. Br J Surg 2003; 90: 680-686.
19. Jurewicz WA. Tacrolimus versus cyclosporine immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 Suppl 1: 7-11.
20. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved graft survival at five years. Transplantation 2002; 73: 775-782.
21. Mayer AD. Chronic rejection and graft half-life: five year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34: 1491-1492.
22. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000; 283: 633-638.
23. Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318: 1104-1107.
24. van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2004; 19 Suppl 6: vi8-vi12.
25. Wu MJ, Shu KH, Cheng CH, Chen CH. Sirolimus in chronic allograft nephropathy. Transplant Proc 2004; 36: 2053-2055.